scispace - formally typeset
L

Liping Zhong

Researcher at Guangxi Medical University

Publications -  55
Citations -  713

Liping Zhong is an academic researcher from Guangxi Medical University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 11, co-authored 31 publications receiving 249 citations.

Papers
More filters
Journal ArticleDOI

Graphene and Au NPs co-mediated enzymatic silver deposition for the ultrasensitive electrochemical detection of cholesterol.

TL;DR: A simple and ultrasensitive cholesterol biosensor based on graphene oxide (GO) and gold nanoparticles (Au NPs) co-mediated enzymatic silver deposition was designed by immobilizing cholesterol oxidase, cholesterol esterase (CHER) and GO onto the surface of Au NPs modified screen-printed carbon electrode (SPE).
Journal ArticleDOI

POD Nanozyme optimized by charge separation engineering for light/pH activated bacteria catalytic/photodynamic therapy

TL;DR: In this paper , a novel Ag/Bi2MoO6 (Ag/BMO) nanozyme optimized by charge separation engineering with photoactivated sustainable peroxidase-mimicking activities and NIR-II photodynamic performance was synthesized by solvothermal reaction and photoreduction.
Journal ArticleDOI

A three-dimensional BODIPY-iron(iii) compound with improved H2O2-response for NIR-II photoacoustic imaging guided chemodynamic/photothermal therapy.

TL;DR: The nanoparticles show good cytotoxic hydroxyl radical (˙OH) generation ability, high photothermal conversion, and outstanding NIR-II photoacoustic imaging, displaying synergistic chemodynamic/photothermal therapy.
Journal ArticleDOI

Copper-doped MOF-Based Nanocomposite for GSH Depleted Chemo/Photothermal/Chemodynamic Combination Therapy

TL;DR: In this paper , a copper-doped ZIF-8-based nanocomposite for cancer combination therapy was constructed, which could deplete over 50% of intracellular glutathione (GSH) to disturb redox homeostasis.
Journal ArticleDOI

A New Theranostic System Based on Endoglin Aptamer Conjugated Fluorescent Silica Nanoparticles.

TL;DR: Both in vitro experiments and in vivo animal studies clearly demonstrated that YQ 26-FSiNPs could achieve prominently high targeting efficiency and therapeutic effects via aptamer YQ26-mediated binding to endoglin (END) molecule.